Leadership Overview
Biogen has 9 executives leading key functions including strategy, finance, legal, and operations.
Driven by a commitment to scientific innovation, Biogen is dedicated to discovering, developing, and delivering therapies for serious neurological and neurodegenerative diseases, aiming to improve patient lives globally through advanced neuroscience research.
Driven by a commitment to scientific innovation, Biogen is dedicated to discovering, developing, and delivering therapies for serious neurological and neurodegenerative diseases, aiming to improve patient lives globally through advanced neuroscience research.
Leadership Roles at Biogen
Christopher Viehbacher - President & Chief Executive Officer
Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the company's overarching strategy and global operations. Viehbacher guides Biogen's mission to discover, develop, and deliver therapies for serious neurological and neurodegenerative diseases. This leadership involves setting the strategic vision for advanced research in neuroscience, biologics, and gene-based therapies. Overseeing all business units, Viehbacher ensures alignment with the company's core purpose of improving patient lives. The Chief Executive Officer's role encompasses driving innovation, fostering a culture of scientific excellence, and managing stakeholder relationships to advance Biogen's market position. Through strategic decision-making, Viehbacher champions the development of treatments for conditions like multiple sclerosis and spinal muscular atrophy. This executive leadership ensures Biogen remains at the forefront of biotechnology, addressing unmet medical needs with cutting-edge solutions. Christopher Viehbacher's tenure focuses on sustainable growth and expanding the company's impact in the rare neurological disorder space.
Andrew McKay - Chief Financial Officer, Biogen (North America)
Andrew McKay, the Chief Financial Officer, Biogen (North America) at Biogen, directs all financial operations and strategic financial planning for the North American region. McKay's responsibilities encompass managing budgets, financial reporting, and investment strategies to support Biogen's growth objectives in key markets. This executive oversees financial performance, ensuring fiscal discipline and maximizing shareholder value. The Chief Financial Officer, Biogen (North America) plays a critical role in resource allocation, guiding investments in research and development, and commercial operations. Andrew McKay's financial leadership is essential for navigating the complex economic landscape of the biotechnology sector. This role involves close coordination with global finance teams to ensure consistent financial policies and practices across the organization. McKay's expertise supports Biogen's mission by ensuring the financial viability of its therapeutic development and commercialization efforts in North America. The strategic financial management provided by Andrew McKay underpins Biogen's ability to deliver innovative treatments.
Robin Kramer - Executive Vice President, Chief Financial Officer
Robin Kramer, the Executive Vice President, Chief Financial Officer at Biogen, leads the company's global financial strategy and operations. Kramer's oversight extends to all aspects of financial management, including accounting, treasury, tax, and investor relations, ensuring robust financial health and strategic resource allocation. This executive role is pivotal in guiding Biogen's financial planning, driving profitability, and supporting long-term sustainable growth. The Chief Financial Officer's responsibilities include managing capital structure, overseeing financial risk, and ensuring compliance with all regulatory requirements. Robin Kramer's financial expertise is instrumental in supporting Biogen's mission to develop and deliver innovative therapies for neurological diseases. This leadership position involves close collaboration with the CEO and the Board of Directors to align financial strategies with corporate objectives. Kramer's stewardship ensures Biogen maintains a strong financial foundation to fund its extensive research and development pipeline. Robin Kramer's strategic financial leadership empowers Biogen to pursue groundbreaking scientific advancements.
Berta Benevento - Deputy Chief Financial Officer
Berta Benevento, the Deputy Chief Financial Officer at Biogen, provides critical support to the Chief Financial Officer in managing the company's global financial operations. Benevento's role involves assisting in the development and execution of financial strategies, overseeing financial reporting, and ensuring the integrity of financial data. This executive contributes to financial planning, budgeting, and forecasting processes, supporting informed decision-making across the organization. The Deputy Chief Financial Officer plays a key part in optimizing financial performance and managing financial risks. Berta Benevento's expertise is vital for maintaining Biogen's financial stability and supporting its investment in cutting-edge neuroscience research. This position requires a deep understanding of financial principles and their application within the biotechnology sector. Benevento works closely with various departments to ensure financial alignment with strategic goals. Berta Benevento's contributions are essential for the efficient and effective management of Biogen's financial resources.
Takatsugu Den - President & Managing Director
Takatsugu Den, the President & Managing Director at Biogen, leads Biogen's operations and strategic initiatives within Japan. Den's role involves overseeing the company's business development, market presence, and operational execution in the Japanese market. This executive is responsible for driving growth and ensuring the successful delivery of Biogen's therapies to patients in Japan. The President & Managing Director, Biogen (Japan) fosters key relationships with healthcare providers, regulatory bodies, and local stakeholders. Takatsugu Den's leadership ensures that Biogen's global mission is effectively translated to meet the specific needs of the Japanese healthcare landscape. This position requires a deep understanding of the local market dynamics and regulatory environment. Den's strategic direction supports Biogen's commitment to advancing neuroscience research and providing treatments for neurological disorders in Japan. Takatsugu Den's management is critical for Biogen's regional success and patient impact.
Wendy Chen - Chief Marketing Officer, Clinical Quality & Manager
Wendy Chen, the Chief Marketing Officer, Clinical Quality & Manager at Biogen, spearheads critical marketing initiatives and ensures the highest standards of clinical quality. Chen's responsibilities include developing and executing comprehensive marketing strategies that align with Biogen's therapeutic focus on neurological and neurodegenerative diseases. This role demands a deep understanding of market dynamics and patient needs within specialized therapeutic areas. Overseeing quality management processes, Wendy Chen ensures that all clinical operations meet rigorous regulatory and ethical standards. The Chief Marketing Officer, Clinical Quality & Manager also manages key operational aspects, driving efficiency and effectiveness across designated functions. This leadership position is vital for translating Biogen's scientific advancements into accessible treatments. Chen's strategic oversight supports the commercial success of Biogen's portfolio, including treatments for multiple sclerosis and spinal muscular atrophy. The integration of marketing prowess with stringent quality control defines this executive's contribution to Biogen's mission.
Krystin Hein - Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US)
Krystin Hein, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) at Biogen, orchestrates strategic planning and operational execution within key medical affairs functions. Hein's role involves driving the strategic direction for rare disease and neuropsychiatry initiatives, particularly within the United States market. This leadership position requires close collaboration with medical affairs teams to ensure the effective development and deployment of therapeutic strategies. Overseeing US operations for neuropsychiatry, Krystin Hein ensures seamless execution of clinical programs and market access initiatives. The Chief of Staff Strategy function supports the executive leadership by streamlining decision-making processes and enhancing organizational efficiency. Hein's focus on rare diseases highlights Biogen's commitment to addressing complex neurological conditions. This executive's strategic acumen is crucial for navigating the intricate landscape of medical affairs and operations in the US. Krystin Hein's leadership ensures that Biogen's medical strategies are effectively implemented to reach patients in need.
Daniel Quirk - Chief Medical Officer, Head of Medical Affairs
Daniel Quirk, the Chief Medical Officer, Head of Medical Affairs at Biogen, leads the company's global medical affairs strategy and execution. Quirk's responsibilities include overseeing clinical development, medical information, and medical education initiatives to support Biogen's therapeutic areas. This executive role is crucial for translating scientific discoveries into effective patient treatments and ensuring the responsible communication of clinical data. The Chief Medical Officer, Head of Medical Affairs directs the medical strategy for Biogen's portfolio, focusing on neurological and neurodegenerative diseases. Daniel Quirk's leadership ensures that medical affairs activities are aligned with patient needs and regulatory requirements. This position involves fostering strong relationships with the medical community and key opinion leaders. Quirk's strategic guidance is essential for advancing Biogen's mission to improve patient outcomes through innovative therapies. Daniel Quirk's medical expertise drives the effective implementation of Biogen's medical strategies worldwide.
Michael Wortley - Chief Legal Officer & Chief Compliance Officer & Executive Vice President
Michael Wortley, the Chief Legal Officer & Chief Compliance Officer & Executive Vice President at Biogen, directs the company's comprehensive legal affairs and compliance programs. Wortley's responsibilities encompass overseeing all legal matters, ensuring adherence to regulatory standards, and managing corporate governance. This executive role is critical for mitigating legal risks and upholding Biogen's ethical commitments across its global operations. The Chief Legal Officer & Chief Compliance Officer & Executive Vice President provides strategic legal counsel to the executive team and the Board of Directors. Michael Wortley's leadership ensures that Biogen operates with the highest standards of integrity and compliance. This position requires extensive expertise in corporate law, intellectual property, and regulatory compliance within the pharmaceutical industry. Wortley's guidance is essential for navigating the complex legal landscape associated with drug development and commercialization. Michael Wortley's legal and compliance oversight safeguards Biogen's reputation and operational integrity.
Explore Leadership Teams in Manufacturing
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The company invests heavily in research and development, maintaining a robust pipeline of innovative medicines and diagnostic solutions while collaborating with academic institutions, biotechnology companies, and healthcare partners worldwide. Headquartered in Basel, Switzerland, Roche operates globally with a presence in numerous countries, employing a diverse workforce of scientists, researchers, healthcare professionals, and business experts dedicated to transforming patient care and making a meaningful difference in the fight against serious diseases.
Company Leadership TH
LA
RL
Md
Sun Pharma is a specialty generic pharmaceutical company that manufactures and distributes pharmaceutical formulations and active pharmaceutical ingredients. It is heaquartered in Mumbia, India.
Company Leadership LK
FN
KS
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, medicated feed additives that offer medicines to livestock; and other pharmaceutical products, which comprise allergy and dermatology, pain and sedation, antiemetic, reproductive, and oncology products. It markets to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company is headquartered in Parsippany, New Jersey.
Company Leadership GT
RV
LP
MT
Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Company Leadership TI
CS
SP
MD
Frequently Asked Questions Regarding Biogen Top Executives and Leadership Team
